内地居民可前往港澳自费接种 mRNA 新冠疫苗复必泰

Zhitong
2022.12.19 10:55
复星医药宣布，mRNA 新冠疫苗复必泰 BNT162b2、复必泰二价疫苗均获正式注册为中国香港药品/制品，分别可用于 12 岁及以上人群的基础免疫接种、加强接种。这意味着，有接种意愿的内地居民可前往中国香港的医疗机构或诊所接种该等疫苗。此前，澳门特区也已向内地居民开放自费接种复必泰疫苗。
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.